Emily Bodnar Analyst PerformanceBiotech Equity Research Analyst at HC WainwrightEmily Bodnar is a stock analyst at HC Wainwright in the medical sector, covering 33 publicly traded companies. Over the past year, Emily Bodnar has issued 66 stock ratings, including strong buy, buy, and hold recommendations. While full access to Emily Bodnar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Bodnar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings111 Last 1 YearsBuy Recommendations90.09% 100 Buy RatingsCompanies Covered33 Unique Companies Ratings Distribution111RatingsDistribution of strong buy, buy, hold, and sell ratings by Emily Bodnar.RatingPercentageCount Strong Buy0.9%1 ratings Buy89.2%99 ratings Hold9.9%11 ratings Sell0.0%0 ratingsOut of 111 total stock ratings issued by Emily Bodnar at HC Wainwright, the majority (89.2%) have been Buy recommendations, followed by 9.9% Hold and 0.9% Strong Buy.Best & Worst CallsBest Call0000.0%OLMAMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RNAZFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ97.0% of companies on NASDAQ32 companiesNYSE3.0% of companies on NYSE1 companyEmily Bodnar, an analyst at HC Wainwright, currently covers 33 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical33 companies100.0%Emily Bodnar of HC Wainwright specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE28 companies84.8%MED - DRUGS3 companies9.1%BIOTECHNOLOGY1 company3.0%MED INSTRUMENTS1 company3.0% About Emily BodnarEmily Bodnar is a Vice President of Equity Research at H.C. Wainwright who joined the firm in January 2022. Ms. Bodnar’s research focuses on the Biotechnology and Women’s Healthcare industries. Prior to joining H.C. Wainwright, Ms. Bodnar was a Senior Equity Research Associate at Cantor Fitzgerald assisting in coverage of small/mid and large-cap biotechnology companies. Ms. Bodnar also worked as an Equity Research Associate at Berenberg Capital Markets assisting in coverage of small/mid-cap biotechnology companies. Ms. Bodnar graduated summa cum laude from Binghamton University where she received a Bachelor of Science. Ms. Bodnar has also taken several Biology and Immunology courses from Johns Hopkins University and Rice University.Follow on LinkedIn Emily Bodnar's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsINKTMiNK Therapeutics5/18/2026Reiterated Rating$10.48$35.00Buy$0.0000.00% ROIAUTLAutolus Therapeutics5/14/2026Boost Price Target$1.59$10.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/12/2026Boost Price Target$3.60$10.00Buy$0.0000.00% ROIARTVArtiva Biotherapeutics5/8/2026Boost Price Target$11.85$35.00Buy$0.0000.00% ROITGTXTG Therapeutics5/6/2026Boost Price Target$39.69$70.00Buy$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/28/2026Initiated Coverage$18.10$30.00Buy$0.0000.00% ROITRAXFirst Tracks Biotherapeutics4/28/2026Upgrade$20.05$30.00Strong-Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals4/20/2026Lower Price Target$27.11$50.00Buy$0.0000.00% ROIINKTMiNK Therapeutics4/1/2026Reiterated Rating$10.53$35.00Buy$0.0000.00% ROIANABAnaptysBio3/30/2026Reiterated Rating$57.40$66.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. ATOSAtossa Genetics3/26/2026Boost Price Target$5.42$25.00Buy$0.0000.00% ROIPPBTPurple Biotech3/13/2026Lower Price Target$4.10$30.00Buy$0.0000.00% ROISABSSAB Biotherapeutics3/10/2026Lower Price Target$3.84$7.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/9/2026Lower Price Target$17.25$38.00Buy$0.0000.00% ROISANASana Biotechnology3/4/2026Lower Price Target$3.93$7.00Buy$0.0000.00% ROIANABAnaptysBio3/4/2026Boost Price Target$52.83$66.00Buy$0.0000.00% ROIRCUSArcus Biosciences3/2/2026Reiterated Rating$20.36$32.00Buy$0.0000.00% ROINVCRNovoCure2/26/2026Boost Price Target$13.11$49.00Buy$0.0000.00% ROIACLXArcellx2/23/2026Downgrade$113.84$115.00Neutral$0.0000.00% ROIAUTLAutolus Therapeutics2/17/2026Initiated Coverage$1.40$9.00Buy$0.0000.00% ROIAUTLAutolus Therapeutics2/17/2026Initiated Coverage$1.51$9.00Buy$0.0000.00% ROINVCRNovoCure2/12/2026Boost Price Target$10.50$47.00Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals2/12/2026Boost Price Target$28.71$65.00Buy$0.0000.00% ROIACLXArcellx2/4/2026Reiterated Rating$68.83$115.00Buy$0.0000.00% ROIRAPTRapt Therapeutics1/20/2026Downgrade$57.52$58.00Neutral$0.0000.00% ROINVCRNovoCure1/13/2026Lower Price Target$14.18$39.00Buy$0.0000.00% ROIVTYXVentyx Biosciences1/8/2026Downgrade$13.73$14.00Neutral$0.0000.00% ROIAGIOAgios Pharmaceuticals12/24/2025Boost Price Target$28.85$62.00Buy$0.0000.00% ROIVTVTvTv Therapeutics12/19/2025Reiterated Rating$34.72$47.00Buy$0.0000.00% ROIRCUSArcus Biosciences12/12/2025Boost Price Target$22.39$32.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals12/11/2025Boost Price Target$30.68$45.00Buy$0.0000.00% ROIACRVAcrivon Therapeutics11/25/2025Reiterated Rating$2.36$19.00Buy$0.0000.00% ROIANABAnaptysBio11/24/2025Lower Price Target$39.61$51.00Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals11/20/2025Lower Price Target$22.34$48.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals11/18/2025Boost Price Target$19.85$36.00Buy$0.0000.00% ROIARTVArtiva Biotherapeutics11/12/2025Boost Price Target$3.65$15.00Buy$0.0000.00% ROIANABAnaptysBio11/11/2025Lower Price Target$33.98$52.00Buy$0.0000.00% ROISANASana Biotechnology11/7/2025Lower Price Target$4.05$9.00Buy$0.0000.00% ROICNTXContext Therapeutics11/6/2025Boost Price Target$1.13$5.00Buy$0.0000.00% ROIVTYXVentyx Biosciences11/5/2025Upgrade$8.09$18.00Buy$0.0000.00% ROII’m sounding the alarm (Ad)Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement.Watch Stansberry's full investigation and see which companies to buy and sellNVCRNovoCure10/30/2025Boost Price Target$12.79$42.00Buy$0.0000.00% ROIRCUSArcus Biosciences10/29/2025Boost Price Target$19.89$28.00Buy$0.0000.00% ROIRAPTRapt Therapeutics10/27/2025Boost Price Target$30.11$72.00Buy$0.0000.00% ROIAGENAgenus10/20/2025Reiterated Rating$3.88Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals10/20/2025Reiterated Rating$9.36$28.00Buy$0.0000.00% ROISNTISenti Biosciences10/14/2025Initiated Coverage$1.68$12.00Buy$0.0000.00% ROITGTXTG Therapeutics10/6/2025Initiated Coverage$36.71$60.00Buy$0.0000.00% ROITGTXTG Therapeutics10/6/2025Initiated Coverage$36.76$60.00Buy$0.0000.00% ROIANABAnaptysBio9/30/2025Boost Price Target$23.27$59.00Buy$0.0000.00% ROIIOBTIO Biotech9/29/2025Downgrade$0.35Neutral$0.0000.00% ROIAGENAgenus9/10/2025Reiterated Rating$5.07$23.00Buy$0.0000.00% ROIAGIOAgios Pharmaceuticals9/4/2025Reiterated Rating$35.90$56.00Buy$0.0000.00% ROIAGENAgenus8/28/2025Reiterated Rating$4.54$23.00Buy$0.0000.00% ROIINKTMiNK Therapeutics8/15/2025Upgrade$15.32$35.00Buy$0.0000.00% ROIVTVTvTv Therapeutics8/13/2025Reiterated Rating$14.50$36.00Buy$0.0000.00% ROIFEMYFemasys8/11/2025Lower Price Target$0.85$8.00Buy$0.0000.00% ROICNTXContext Therapeutics8/7/2025Lower Price Target$0.70$4.00Buy$0.0000.00% ROISABSSAB Biotherapeutics7/22/2025Lower Price Target$2.70$9.00Buy$0.0000.00% ROIINKTMiNK Therapeutics7/15/2025Downgrade$29.53$35.00Neutral$0.0000.00% ROIJSPRJasper Therapeutics7/7/2025Lower Price Target$3.04$20.00Buy$0.0000.00% ROINXTCNextCure7/1/2025Reiterated Rating$5.52$36.00Buy$0.0000.00% ROIFEMYFemasys6/25/2025Reiterated Rating$0.95$12.00Buy$0.0000.00% ROIACLXArcellx6/16/2025Reiterated Rating$66.00$115.00Buy$0.0000.00% ROIFEMYFemasys6/11/2025Reiterated Rating$0.84$12.00Buy$0.0000.00% ROIAGENAgenus6/4/2025Upgrade$5.00$25.00Buy$0.0000.00% ROISABSSAB Biotherapeutics5/14/2025Initiated Coverage$1.80$10.00Buy$0.0000.00% ROIAGENAgenus5/13/2025Reiterated Rating$3.50Neutral$0.0000.00% ROIFEMYFemasys5/9/2025Lower Price Target$1.16$12.00Buy$0.0000.00% ROIAGENAgenus4/30/2025Reiterated Rating$3.05Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals4/28/2025Reiterated Rating$4.91$30.00Buy$00.0000.00% ROISANASana Biotechnology4/24/2025Reiterated Rating$1.71$11.00Buy$0.0000.00% ROIBCTXBriacell Therap4/22/2025Reiterated Rating$48.03$320.00Buy$0.0000.00% ROIRNAZTransCode Therapeutics4/16/2025Lower Price Target$11.14$280.00Buy$0.0000.00% ROIVTVTvTv Therapeutics4/9/2025Initiated Coverage$15.80$36.00Buy$00.0000.00% ROIIOBTIO Biotech4/1/2025Reiterated Rating$1.09$12.00Buy$0.0000.00% ROIGNLXGenelux3/31/2025Reiterated Rating$3.08$30.00Buy$0.0000.00% ROICNTBConnect Biopharma3/31/2025Reiterated Rating$0.68$8.00Buy$0.0000.00% ROIFEMYFemasys3/28/2025Reiterated Rating$1.34$15.00Buy$0.0000.00% ROINKTXNkarta3/27/2025Reiterated Rating$1.37$18.00Buy$0.0000.00% ROIIMNNImunon3/26/2025Reiterated Rating$15.00$210.00Buy$0.0000.00% ROIACRVAcrivon Therapeutics3/26/2025Lower Price Target$5.39$19.00Buy$0.0000.00% ROIATOSAtossa Genetics3/26/2025Reiterated Rating$10.86$105.00Buy$0.0000.00% ROIGNLXGenelux3/25/2025Reiterated Rating$3.41$30.00Buy$0.0000.00% ROICNTXContext Therapeutics3/21/2025Reiterated Rating$0.77$5.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/19/2025Reiterated Rating$4.14$30.00Buy$00.0000.00% ROIFEMYFemasys3/19/2025Boost Price Target$1.60$15.00Buy$0.0000.00% ROIAGENAgenus3/18/2025Reiterated Rating$1.78Neutral$0.0000.00% ROISANASana Biotechnology3/18/2025Reiterated Rating$2.77$11.00Buy$0.0000.00% ROIINKTMiNK Therapeutics3/18/2025Reiterated Rating$8.06$35.00Buy$0.0000.00% ROINXTCNextCure3/17/2025Reiterated Rating$8.45$36.00Buy$00.0000.00% ROIYour $29.97 book is free today (Ad)Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.Normally $29.97. Today it's free. Grab your copy now.RNAZTransCode Therapeutics3/13/2025Reiterated Rating$25.34$560.00Buy$0.0000.00% ROIFEMYFemasys3/13/2025Reiterated Rating$1.44$12.00Buy$0.0000.00% ROIATOSAtossa Genetics3/12/2025Reiterated Rating$11.11$105.00Buy$0.0000.00% ROIAGENAgenus3/12/2025Reiterated Rating$2.05Neutral$0.0000.00% ROIOLMAOlema Pharmaceuticals3/11/2025Reiterated Rating$4.25$30.00Buy$00.0000.00% ROIJSPRJasper Therapeutics3/11/2025Reiterated Rating$5.14$40.00Buy$0.0000.00% ROINXTCNextCure3/7/2025Reiterated Rating$8.55$36.00Buy$00.0000.00% ROIIOBTIO Biotech3/5/2025Reiterated Rating$0.91$12.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals3/5/2025Reiterated Rating$4.18$30.00Buy$00.0000.00% ROIFEMYFemasys2/26/2025Reiterated Rating$1.58$12.00Buy$0.0000.00% ROIINKTMiNK Therapeutics2/25/2025Boost Price Target$10.65$35.00Buy$00.0000.00% ROIAGIOAgios Pharmaceuticals2/24/2025Initiated Coverage$35.22$58.00Buy$00.0000.00% ROIFEMYFemasys2/11/2025Reiterated Rating$1.26$12.00Buy$0.0000.00% ROIRNAZTransCode Therapeutics2/6/2025Reiterated Rating$321.02$560.00Buy$0.0000.00% ROITNYATenaya Therapeutics2/3/2025Reiterated Rating$1.05$18.00Buy$0.0000.00% ROIBCTXBriacell Therap2/3/2025Boost Price Target$50.80$320.00Buy$0.0000.00% ROIATOSAtossa Genetics1/30/2025Reiterated Rating$12.84$105.00Buy$0.0000.00% ROIAGENAgenus1/22/2025Reiterated Rating$3.83Neutral$0.0000.00% ROIVTYXVentyx Biosciences1/14/2025Reiterated Rating$1.95Neutral$00.0000.00% ROIJSPRJasper Therapeutics1/10/2025Lower Price Target$6.99$40.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupThe Goldman Sachs GroupDeutsche Bank AktiengesellschaftCLSAWall Street ZenCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupTD CowenTruist FinancialPiper Sandler Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.